Sec­tion 7. Di­a­betes Tech­nol­o­gy

(https:/​/​doi.org/​10.2337/​dc23-​S007)

The im­por­tance of “pref­er­ence” for di­a­betes de­vices was added in all rec­om­men­da­tions.

Rec­om­men­da­tion 7.12 for the use of con­tin­u­ous glu­cose mon­i­tor­ing (CGM) in adults with di­a­betes treat­ed with basal in­sulin was re­word­ed to reflect up­dat­ed ev­i­dence in the lit­er­a­ture.

Rec­om­men­da­tion 7.15 was modified to state that peo­ple with di­a­betes should have un­in­ter­rupt­ed ac­cess to their sup­plies to min­i­mize gaps in CGM use.

Rec­om­men­da­tion 7.19 was added to ad­dress CGM in­ter­fer­ing sub­stances, with ev­i­dence lev­el C.

A new para­graph ad­dress­ing sub­stances and fac­tors af­fect­ing CGM ac­cu­ra­cy was added to the “Con­tin­u­ous Glu­cose Mon­i­tor­ing De­vices” sub­sec­tion. Table 7.4 was added to ad­dress in­ter­fer­ing sub­stances for CGM.

In­for­ma­tion was added on all three in­te­grat­ed CGM de­vices avail­able, and it was specified that al­though there is more than one CGM sys­tem ap­proved by the U.S. Food and Drug Ad­min­is­tra­tion (FDA) for use with au­to­mat­ed in­sulin de­liv­ery sys­tems, only one sys­tem with in­te­grat­ed CGM des­ig­na­tion is FDA ap­proved for use with au­to­mat­ed in­sulin de­liv­ery sys­tems.

Lit­er­a­ture and in­for­ma­tion was added on benefits on glycemic out­comes of ear­ly ini­ti­a­tion of real-​time CGM in chil­dren and adults and the need to con­tin­ue CGM use to max­i­mize benefits.

The para­graph on con­nect­ed pens was up­dat­ed to in­clude smart pen caps. Ref­er­ences were up­dat­ed for au­to­mat­ed in­sulin de­liv­ery sys­tems to in­clude all the ap­proved sys­tems in the U.S. in 2022.

The text was up­dat­ed to in­clude do-it-​your­self closed loop sys­tems.

The “In­pa­tient Care” sub­sec­tion was up­dat­ed to in­clude up­dat­ed ev­i­dence and a para­graph on the use of CGM in the in­pa­tient set­ting dur­ing the COVID-​19 pan­dem­ic.